Undifferentiated sarcoma is a rare and aggressive type of cancer that develops in the body’s soft tissues or, less commonly, in bones. Treatment typically combines surgery, radiation therapy, and sometimes chemotherapy or newer immunotherapy approaches, with the goal of removing the tumor, preventing its return, and improving quality of life.

How Treatment Choices Are Made for Undifferentiated Sarcoma

When someone receives a diagnosis of undifferentiated sarcoma, also known as undifferentiated pleomorphic sarcoma or UPS, the treatment approach depends on several important factors. These include where the tumor is located in the body, how large it has grown, whether the cancer has spread to other areas such as the lungs or lymph nodes, and the overall health and age of the patient.^[1][2]

The main goal of treatment is to remove the tumor completely while preserving as much normal function as possible. For tumors in the arms or legs, this often means performing limb-sparing surgery so the patient can continue to use the limb. Doctors also aim to prevent the cancer from coming back in the same location, which is called local recurrence, and to stop it from spreading to distant parts of the body, which is known as metastasis. Because undifferentiated sarcoma is an aggressive cancer that can spread quickly, early detection and treatment are essential.^[2][4]

Treatment decisions are made by a team of specialists working together. This multidisciplinary team typically includes surgical oncologists who remove tumors, medical oncologists who prescribe drug treatments, and radiation oncologists who deliver radiation therapy. Pathologists also play a key role by examining tissue samples under a microscope to confirm the diagnosis and rule out other types of cancer. This teamwork ensures that each patient receives a comprehensive, personalized treatment plan.^[10][15]

Standard Treatment Approaches

Surgery as the Primary Treatment

Surgery is the cornerstone of treatment for undifferentiated sarcoma when the tumor has not spread to other parts of the body. The surgeon’s goal is to remove the entire tumor along with a surrounding margin of healthy tissue. This margin, sometimes called a “clear margin,” helps ensure that no cancer cells are left behind. Achieving clear margins reduces the risk that the tumor will grow back in the same spot.^[2][12]

For sarcomas located in the arms or legs, surgeons perform limb-sparing procedures whenever possible. This means removing the tumor while keeping the limb functional. In rare cases where the cancer has spread extensively throughout the limb and cannot be safely removed otherwise, a partial or complete amputation may be necessary to prevent further spread of the disease.^[3][20]

Before surgery, careful planning is essential. If a biopsy is needed to confirm the diagnosis, it must be done in a way that does not interfere with the later surgical removal of the tumor. This is why patients are often referred to specialized sarcoma centers where experienced teams can coordinate all aspects of care.^[10][18]

Radiation Therapy

Radiation therapy uses high-energy beams to destroy cancer cells. It is often combined with surgery to improve outcomes for patients with undifferentiated sarcoma. Radiation can be given either before or after surgery, and the timing depends on the specific situation.^[3][12]

When radiation is delivered before surgery, it is called neoadjuvant radiation. The purpose is to shrink the tumor, making it easier to remove and increasing the chances of achieving clear margins. When radiation is given after surgery, it is called adjuvant radiation. In this case, the goal is to kill any remaining cancer cells that may not have been removed during the operation, thereby reducing the risk of local recurrence.^[13][20]

Some specialized centers offer proton therapy, a type of radiation that precisely targets the tumor while avoiding surrounding healthy organs and tissues. This approach can lead to fewer short-term side effects and long-term complications compared to traditional radiation. Proton therapy is particularly beneficial for tumors located near sensitive structures or in pediatric patients.^[3][13]

Side effects of radiation therapy can include fatigue, skin changes in the treated area, and temporary swelling. Most side effects improve after treatment ends, though some patients may experience long-term effects such as stiffness or changes in skin texture.

Chemotherapy

Chemotherapy involves the use of drugs that kill cancer cells or stop them from growing. For undifferentiated sarcoma, chemotherapy is sometimes used when the cancer is at high risk of spreading or has already spread to other parts of the body, such as the lungs. It may also be considered for patients with large, high-grade tumors.^[2][3]

Traditional chemotherapy drugs for sarcoma include anthracyclines (such as doxorubicin), which are among the most commonly used agents. Other options include alkylating agents and topoisomerase inhibitors. These drugs work by interfering with cancer cell division, but they can also affect healthy cells, leading to side effects such as fatigue, hair loss, nausea, and a weakened immune system.^[14]

The decision to use chemotherapy depends on factors such as tumor size, location, grade, and whether the cancer has metastasized. While chemotherapy has been a mainstay of sarcoma treatment for many years, response rates can be limited, and not all patients benefit from it. This has led researchers to explore newer, more targeted treatment approaches.^[14]

Treatment in Clinical Trials

Immunotherapy: A Promising New Approach

One of the most exciting developments in the treatment of undifferentiated pleomorphic sarcoma is the use of immunotherapy. Immunotherapy works by helping the patient’s own immune system recognize and attack cancer cells. Unlike traditional chemotherapy, which directly kills cancer cells but can also harm healthy tissue, immunotherapy harnesses the body’s natural defenses with a more targeted approach.^[14][15]

Research has shown that some patients with undifferentiated pleomorphic sarcoma respond well to immunotherapy. One major clinical trial that explored this was the SARC028 trial, which enrolled patients with various types of soft tissue sarcoma, including UPS. The trial tested a type of immunotherapy drug called a checkpoint inhibitor, which blocks proteins that prevent the immune system from attacking cancer cells. Results from this trial and similar studies suggest that certain sarcoma subtypes, including UPS, may be more responsive to immunotherapy than others.^[14]

One specific immunotherapy drug that has been studied is pembrolizumab, a checkpoint inhibitor that targets a protein called PD-1. By blocking PD-1, pembrolizumab allows immune cells to recognize and destroy cancer cells more effectively. Case reports have described patients with metastatic UPS who received pembrolizumab for extended periods—in some instances for more than six years—with good responses and minimal side effects. In these cases, immunotherapy was sometimes combined with radiation therapy to treat tumors that did not respond completely to immunotherapy alone.^[14]

Unlike chemotherapy, which is associated with side effects such as hair loss and severe fatigue, immunotherapy generally has a different side effect profile. The main risks involve inflammatory reactions, such as skin rashes, inflammation of the lungs or intestines, or changes in thyroid function. However, many patients tolerate immunotherapy well, and serious side effects are relatively uncommon, especially when detected and managed early.^[14]

How Long Should Immunotherapy Continue?

One question that researchers are still working to answer is how long immunotherapy should be continued in patients who are responding well. For many cancers, immunotherapy is given for a defined period, such as two years. However, for undifferentiated sarcoma, there is less guidance. Some patients have been treated successfully for much longer periods without experiencing serious adverse effects, suggesting that extended treatment may be safe and beneficial when it is well tolerated.^[14]

The decision about treatment duration is individualized and depends on factors such as how well the cancer is responding, whether there are side effects, and the patient’s overall health. Ongoing research is needed to establish clearer guidelines for the optimal duration of immunotherapy in sarcoma patients.

Combining Immunotherapy with Other Treatments

In some cases, immunotherapy is used together with other treatment modalities such as radiation therapy or surgery. This multimodal approach can be particularly useful when the cancer responds partially to immunotherapy but some areas of disease remain. Adding radiation to treat these residual areas can help achieve better overall control of the cancer.^[14][15]

Researchers are also exploring whether giving immunotherapy before surgery, in what is called the neoadjuvant setting, can improve outcomes. The idea is that by stimulating the immune system before the tumor is removed, it may be possible to reduce the size of the tumor and decrease the risk of recurrence. Clinical trials are underway to test this approach in patients with undifferentiated pleomorphic sarcoma of the extremities.^[15]

Clinical Trial Phases and What They Mean

Clinical trials for new treatments typically progress through several phases. Phase I trials focus on safety, testing a new drug or treatment in a small group of people to determine the right dose and identify side effects. Phase II trials evaluate whether the treatment works, enrolling more patients to assess effectiveness. Phase III trials compare the new treatment to standard therapies in large groups of patients to determine if it offers better outcomes.^[4]

For undifferentiated sarcoma, immunotherapy drugs such as checkpoint inhibitors have moved through these phases and are now being studied in combination with other treatments. While not all sarcoma subtypes respond equally to immunotherapy, undifferentiated pleomorphic sarcoma appears to be one of the more responsive types, making it a focus of ongoing research.

Other Innovative Approaches Being Studied

Beyond immunotherapy, researchers are exploring other innovative treatment strategies for undifferentiated sarcoma. These include targeted therapies that focus on specific genetic or molecular abnormalities within cancer cells. However, unlike some other cancers, undifferentiated pleomorphic sarcoma does not have consistent genetic markers that can be easily targeted. The cancer cells have highly complex and disorganized genetic changes, making it challenging to identify specific targets for therapy.^[4][7]

Despite this challenge, scientists continue to study the genetic landscape of UPS to identify potential vulnerabilities. Advanced techniques such as whole-genome sequencing have revealed that these tumors undergo dramatic genetic rearrangements, and understanding these processes may eventually lead to new treatment options.^[7]

Most Common Treatment Methods

• Surgery
  • Surgical removal of the tumor with clear margins is the primary treatment for undifferentiated sarcoma
  • Limb-sparing surgery is performed whenever possible for tumors in the arms or legs
  • Amputation may be necessary in rare cases where the cancer has spread extensively throughout the limb
  • Careful biopsy planning is essential to avoid interfering with later surgical removal
• Radiation Therapy
  • High-energy beams are used to destroy cancer cells before or after surgery
  • Neoadjuvant radiation is given before surgery to shrink the tumor
  • Adjuvant radiation is given after surgery to kill remaining cancer cells
  • Proton therapy is a specialized form that targets tumors precisely while avoiding healthy tissue
• Chemotherapy
  • Used for high-risk tumors or when cancer has spread to other parts of the body
  • Anthracyclines such as doxorubicin are commonly used drugs
  • Can cause side effects including fatigue, hair loss, nausea, and immune suppression
  • Response rates are variable, leading to interest in newer treatment approaches
• Immunotherapy
  • Checkpoint inhibitors such as pembrolizumab help the immune system attack cancer cells
  • Tested in clinical trials such as SARC028 with promising results for UPS
  • Can be given for extended periods with generally good tolerance
  • Sometimes combined with radiation therapy for mixed responses
  • Side effects involve inflammatory reactions rather than traditional chemotherapy effects